Regentis Inks Four-Year Exclusive Distribution Deal for GelrinC in Israel, Targeting 2027 Revenue

Regentis Biomaterials has signed a four-year exclusive distribution agreement with AMI Medical Technologies to commercialize its GelrinC knee cartilage implant in Israel, marking a key step in the company's global commercialization strategy.

Chicago Metrowire Staff
••Healthcare
Regentis Inks Four-Year Exclusive Distribution Deal for GelrinC in Israel, Targeting 2027 Revenue

Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC® in Israel. GelrinC is Regentis' proprietary implant for repairing damaged knee cartilage and has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States.

Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals and clinics to support the product's commercial introduction. The deal includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance.

The agreement supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The product is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.

For investors, the exclusive distribution deal provides a clear pathway to revenue in a new market and validates the company's regulatory and commercial strategy. The inclusion of minimum purchase requirements reduces commercial risk and signals AMI's confidence in the product's potential. The collaboration on reimbursement coverage is critical for adoption, as it will determine how quickly patients can access GelrinC through Israel's health system. The expected 2027 revenue timeline aligns with the company's broader goal of building momentum ahead of a potential U.S. market entry.

Regentis is featured on BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. For more information, visit https://www.BioMedWire.com.

Blockchain Registration

QR Code for Blockchain Registration